Filed Pursuant to Rule 424(b)(5)
Registration No. 333-222648
The information in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not offers to sell these securities and we are not soliciting offers to buy these securities in any jurisdiction where the offer or sale is not permitted.
SUBJECT TO COMPLETION, DATED NOVEMBER 16, 2020
Prospectus Supplement
(to Prospectus dated January 22, 2018)

Assurant, Inc.
$ % Subordinated Notes due 2061
Assurant, Inc. is offering $ principal amount of % subordinated notes due 2061 (the “Notes”). We will pay interest on the Notes quarterly in arrears on , , and of each year, beginning on , 2021. The Notes will mature on , 2061.
So long as no event of default with respect to the Notes has occurred and is continuing, we have the right, on one or more occasions, to defer the payment of interest on the Notes as described in this prospectus supplement for one or more consecutive interest periods for up to five years. Deferred interest will accrue additional interest at an annual rate equal to the annual interest rate of the Notes. See “Description of the Notes—Option to Defer Interest Payments.”
The principal amount of the Notes will mature on , 2061. Payment of the principal on the Notes will be accelerated only in the case of an event of default defined as a bankruptcy of or certain other insolvency events with respect to Assurant, Inc. as described in this prospectus supplement. There is no right of acceleration in the case of a default in the payment of interest on the Notes or the performance of any of our other obligations with respect to the Notes.
We may redeem the Notes, in whole, but not in part, at any time prior to , 2026, within 90 days after the occurrence of a “rating agency event,” a “tax event” or a “regulatory capital event” at a redemption price equal to (i) with respect to a “rating agency event,” 102% of their principal amount, and (ii) with respect to a “tax event” or a “regulatory capital event,” their principal amount, in each case plus accrued and unpaid interest (including compounded interest) to, but excluding, the date of redemption. On or after , 2026, we may redeem the Notes, in whole at any time or in part from time to time, at a redemption price equal to their principal amount plus accrued and unpaid interest (including compounded interest) to, but excluding, the date of redemption; provided that if the Notes are not redeemed in whole, at least $25 million aggregate principal amount of the Notes, excluding any Notes held by us or any of our affiliates, must remain outstanding after giving effect to such redemption. For more information and the definitions of “rating agency event,” “tax event” and “regulatory capital event,” see “Description of the Notes—Redemption” in this prospectus supplement. The Notes will be issued in denominations of $25 and in integral multiples in excess thereof.
The Notes will be unsecured, will rank equally in right of payment to all our existing and future pari passu securities (as defined herein) and will be subordinated and junior in right of payment to all our existing and future senior indebtedness (as defined herein). The subordinated notes indenture (as defined herein) places no limitation on the amount of senior or pari passu indebtedness we may incur.
We intend to use the net proceeds of this offering, along with cash on hand, to finance our pending acquisition of Hyla, Inc. (the “Hyla Acquisition”). Any remaining net proceeds will be used for general corporate purposes. See “Use of Proceeds.”
The closing of this offering is not conditioned on the consummation of the Hyla Acquisition, which, if consummated, will occur subsequent to the closing of this offering.
See “Risk Factors” on page S-8 of this prospectus supplement and page 4 of the accompanying prospectus to read about factors you should consider before investing in the Notes.
Neither the Securities and Exchange Commission (the “SEC”) nor any other regulatory body has approved or disapproved of these securities or passed upon the accuracy or adequacy of this prospectus supplement or the accompanying prospectus. Any representation to the contrary is a criminal offense.
We intend to apply to list the Notes on the New York Stock Exchange (the “NYSE”). If approved for listing, trading on the NYSE is expected to begin within 30 business days of , 2020, the original issue date.
| | | | | | | | |
| | Per Note | | | Total (3) | |
Public offering price (1) | | | | % | | $ | | |
Underwriting discount (2) | | | | % | | $ | | |
Proceeds to Assurant, Inc. (before expenses) | | | | % | | $ | | |
(1) | Plus accrued interest, if any, from and including , 2020, if settlement occurs after that date. |
(2) | Reflects $ aggregate principal amount of Notes sold to retail investors, for which the underwriters received an underwriting discount of $ per Note, and $ aggregate principal amount of Notes sold to institutional investors, for which the underwriters received an underwriting discount of $ per Note. Underwriting discount per Note is calculated using a weighted average underwriting discount for retail and institutional investors. |
(3) | Assumes no exercise of the underwriters’ option to purchase additional Notes as described herein. |
We have granted the underwriters an option to purchase up to an additional $ aggregate principal amount of Notes within 30 days from the date of this prospectus supplement solely to cover overallotments.
The underwriters expect to deliver the Notes to purchasers through the book-entry delivery system of The Depository Trust Company for the accounts of its participants, including Clearstream Banking, S.A., and Euroclear Bank SA/NV, on or about , 2020, against payment in immediately available funds.
Joint Book-Running Managers
| | | | |
Wells Fargo Securities | | Morgan Stanley | | J.P. Morgan |
The date of this prospectus supplement is , 2020